Charles Schwab Investment Management Inc Viridian Therapeutics, Inc.\De Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 483,921 shares of VRDN stock, worth $11.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
483,921
Previous 424,085
14.11%
Holding current value
$11.3 Million
Previous $7.43 Million
15.22%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VRDN
# of Institutions
149Shares Held
60.7MCall Options Held
134KPut Options Held
238K-
Black Rock Inc. New York, NY4.77MShares$111 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$91.5 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$90.6 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$78.1 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.31MShares$77.2 Million0.85% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $931M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...